Sentinel lymph node biopsy: Preferred method of axillary staging for breast cancer

Minerva Ginecologica

Volumn 57, Issue 3, 2005, Pages 293-303

  Tuttle, T M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Breast neoplasms, diagnosis; Breast neoplasms, histology; Lymph node biopsy

Indexed keywords

AXILLARY LYMPH NODE; BIOPSY TECHNIQUE; BLEEDING; BREAST CANCER; CANCER STAGING; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MALE BREAST; MINIMALLY INVASIVE SURGERY; MORBIDITY; PARESTHESIA; PNEUMOTHORAX; RARE DISEASE; RECURRENCE RISK; REVIEW; SCAR FORMATION; SENTINEL LYMPH NODE;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY;

EID: 27144489434     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Kakuda JT, Stuntz M, Trivedi V, Klein SR, Vargas HI. Objective assessment of axillary morbidity in breast cancer treatment. Am Surg 1999;65:995-8.
2. Hoe AL, Iven D, Royle GT, Taylor I. Incidence of arm swelling following axillary clearance for breast cancer. Br J Surg 1992;79:261-2.
3. Martin RC 2nd, Edwards MJ, Wong SL, Tuttle TM, Carlson DJ, Brown CM et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study, for the University of Louisville Breast Cancer Study Group. Surgery 2000;128:139-44.
4. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000;18:2560-6.
5. McMasters KM, Wong SL, Tuttle TM, Carlson DJ, Brown CM, Dirk Noyes et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg 2000;231:724-31.
6. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998;339:941-6.
7. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-9; discussion 340.
8. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-8; discussion 398-401.
9. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
10. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-9; discussion 340.
11. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
12. Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997;3:336-40.
13. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998;186:275-83.
14. Krag DN, Ashikaga T, Harlow SP, Weaver DL. Development of sentinel node targeting technique in breast cancer patients. Breast J 1998;4:67-74.
15. Bass SS, Cox CE, Ku NN, Berman C, Reinigen DS. The role of sentinel lymph node biopsy in breast cancer. J Am Coll Surg 1999;189:183-94.
16. Kollias J, Gill PG, Chatterton BE, Hall VE, Bochner MA, Coventry BJ et al. Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancer. Med J Aust 1999;171:461-5.
17. Noguchi M, Motomura K, Imoto S, Miyauchi M, Sato K, Iwata H et al. A multicenter validation study of sentinel lymph node biopsy by the Japanese breast cancer society. Breast Cancer Res Treat 2000;63:31-40.
18. Fraile M, Rull M, Julian FJ, Fuste F, Barnadas A, Llatjos M et al. Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: An approach to its validity. Ann Oncol 2000;11:701-5.
19. McMasters KM, Wong SL, Martin RC 2nd, Chao C, Tuttle TM, Noyes RD et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001;233:676-87.
20. Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233:51-9.
21. Ahrendt GM, Laud P, Tjoe J, Eastwood D, Walker AP, Otterson MF et al. Does breast tumor location influence success of sentinel lymph node biopsy? J Am Coll Surg 2002;194:278-84.
22. Shivers S, Cox C, Leight G, Beauchamp D, Blumencranz P, Ross M et al. Final results of the department of defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 2002;9:248-55.
23. McMasters KM, Wong SL, Chao C, Woo C, Tuttle TM, Noyes RD et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg 2001;234:292-9; discussion 299-300.
24. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-7.
25. Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph-node in breast cancer. Lancet 1997;349:1668-69.
26. Linehan DC, Hill AD, Akhurst T, Yeung H, Yeh SD, Tran KN et al. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol 1999;6:450-4.
27. Casalegno PS, Sandrucci S, Bello M, Durando A, Danese S, Silvestro L et al. Sentinel lymph node and breast cancer staging: Final results of the turin multicenter study. Tumori 2000;86:300-3.
28. Boolbol SK, Fey JV, Borgen PI, Heerdt AS, Montgomery LL, Paglia M et al. Intradermal isotope injection: a highly accurate method of lymphatic mapping in breast carcinoma. Ann Surg Oncol 2001;8:20-4.
29. Martin RC, Derossis AM, Fey J, Yeung H, Yeh SD, Akhurst T et al. Intradermal isotope injection is superior to intramammary in sentinel node biopsy for breast cancer. Surgery 2001;130:432-8.
30. Vargas HI, Vargas MP, Gonzalez KD, Burla M, Venegas R, Diggles L et al. Immediate preoperative injection of 99m-tc sulfur colloid is effective in the detection of breast sentinel lymph nodes. Am Surg 2002;68:1083-7.
31. Kern KA. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye. J Am Coll Surg 1999;189:539-45.
32. Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999;229:860-4; discussion 864-5.
33. Smith LF, Cross MJ, Klimberg VS. Subareolar injection is a better technique for sentinel lymph node biopsy. Am J Surg 2000;180:434-7; discussion 437-8.
34. Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg 2000;232:81-9.
35. Beitsch PD, Clifford E, Whitworth P, Abarca A. Improved lymphatic mapping technique for breast cancer. Breast J 2001;7:219-23.
36. Tuttle TM, Colbert M, Christensen R, Ose KJ, Jones T, Wetherille R et al. Subareolar injection of 99mTc facilitates sentinel lymph node identification. Ann Surg Oncol 2002;9:77-81.
37. Bauer TW, Spitz FR, Callans LS, Alavi A, Mick R, Weinstein SP et al. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol. 2002;9:169-76.
38. Chagpar A, Martin RC 3rd, Chao C, Wong SL, Edwards MJ, Tuttle T et al. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg 2004;139:614-8; discussion 618-20.
39. Zogakis T, Wetherille R, Christensen R, Ose K, Friedman J, Colbert M et al. Intraoperative subareolar technetium injection results in consistent sentinel lymph node identification. Ann Surg Oncol 2005;12:167-72. Epub 2005 Jan 25.
40. Kern KA, Rosenberg RJ. Preoperative lymphoscintigraphy during lymphatic mapping for breast cancer: improved sentinel node imaging using subareolar injection of technetium 99m sulfur colloid. J Am Coll Surg 2000;191:479-89.
41. Kern KA. Breast lymphatic mapping using subareolar injections of blue dye and radiocolloid: Illustrated technique. J Am Coll Surg 2001;192:545-50.
42. McCarter MD, Yeung H, Yeh S, Fey J, Borgen PI, Cody HS 3rd. Localization of the sentinel node in breast cancer: identical results with same-day and day-before isotope injection. Ann Surg Oncol 2001;8:682-6.
43. Cody HS, 3rd, Fey J, Akhurst T, Fazzari M, Mazumdar M, Yeung H et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 2001;8:13-9.
44. Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Woo et al. Predicting the status of the nonsentinel axillary nodes: a multicenter study. Arch Surg 2001;136:563-8.
45. Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg 2001;192:684-9; discussion 689-91.
46. Montgomery LL, Thorne AC, Van Zee KJ, Fey J, Heerdt AS, Gemignani M et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 2002;95:385-8, table of contents.
47. Simmons R, Thevarajah S, Brennan MB, Christos P, Osborne M. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol 2003;10:242-7.
48. Stradling B, Aranha G, Gabram S. Adverse skin lesions after methylene blue injections for sentinel lymph node localization. Am J Surg 2002;184:350-2.
49. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M et al. Role of immunohistochemical detection of lymphnode metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999;354:896-900.
50. Greene FL, Page DL, Fleming ID, Fritz A, Balch CH, Haller DG et al. AJCC Cancer Staging Manual, 6Th Edition. New York: Springer-Verlag; 2002.
51. Gentilini O, Cremonesi M, Trifiro G, Ferrari M, Baio SM, Caracciolo M et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 2004;15:1348-51.
52. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol 2001;8:688-92.
53. Goyal A, Horgan K, Kissin M, Yiangou C, Sibbering M, Lansdown M et al. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol 2004;30:480-3.
54. Intra M, Veronesi P, Mazzarol G, Galimberti V, Luini A, Sacchini V et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003;138:309-13.
55. Cox CE, Nguyen K, Gray RJ, Salud C, Ku NN, Dupont E et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg 2001;67:513-9; discussion 519-21.
56. Kelley MC, Hansen N, McMasters KM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Am J Surg. 2004;188:49-61.
57. Patel NA, Piper G, Patel JA, Malay MB, Julian TB. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer. Am Surg 2004;70:696-9; discussion 699-700.
58. Reitsamer R, Peintinger F, Rettenbacher L, Prokop E. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol 2003;84:63-7.
59. Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002;9:243-7.
60. Haid A, Tausch C, Lang A, Lutz J, Fritzsche H, Peschina W et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 2001;92:1080-4.
61. Balch GC, Mithani SK, Richards KR, Beauchamp RD, Kelley MC. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol 2003;10:616-21.
62. Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 2001;182:312-5.
63. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002;9:235-42.
64. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 2003;83:931-42.
65. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000;89:2187-94.
66. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480-6.
67. Donnelly J, Parham DM, Hickish T, Chan HY, Skene AI. Axillary lymph node scarring and the association with tumour response following neoadjuvant chemoendocrine therapy for breast cancer. Breast 2001;10:61-6.
68. Sabel MS, Schott AF, Kleer CG, Merajver S, Cimmino VM, Diehl KM et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 2003;186:102-5.
69. Tousimis E, Van Zee KJ, Fey JV, Hoque LW, Tan LK, Cody HS 3rd et al. The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers. J Am Coll Surg 2003;197:529-35.
70. Goyal A, Newcombe RG, Mansel RE, Chetty U, Ell P, Fallowfield L et al.; ALMANAC Trialists Group. Sentinel lymph node biopsy in patients with multifocal breast cancer. Eur J Surg Oncol 2004;30:475-9.
71. Swenson KK, Nissen MJ, Ceronsky C, Swenson L, Lee MW, Tuttle TM. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol 2002;9:745-53.
72. Mansel RE, Goyal A, Newcombe RG, Kissin M, Dixon M, Yiangou C et al. Objective assessment of lymphedema, shoulder function, and sensory deficit after sentinel lymph node biopsy for invasive breast cancer: ALMANAC trial. San Antonio Breast Cancer Symposium, 2004. December 8-11, San Antonio, Texas.
73. Veronesi U, Galimberti V, Zurrida S, Pigatto F, Veronesi P, Robertson C et al. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer 2001;37:454-8.
74. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;18:2553-9.
75. Reynolds C, Mick R, Donohue JH, Grant CS, Parley DR, Callans LS et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 1999;17:1720-6.
76. Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC et al. Pathologic features associated with non-sentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000;89:574-81.
77. Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003;10:1140-51.
78. Abdessalam SF, Zervos EE, Prasad M, Farrar WB, Yee LD, Walker MJ et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg 2001;182:3l6-20.
79. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-41.
80. Degnim AC, Griffith KA, Sabel MS, Hayes DF, Cimmino VM, Diehl KM et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 2003;98:2307-15.
81. Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 2003;10:248-54.
82. Kamath VJ, Giuliano R, Dauway EL, Cantor A, Berman C, Ku NN et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 2001;136:688-92.
83. Wangensteen OH. Remarks on carcinoma of the breast: fifty years' experience at the massachusetts general hospital. Ann Surg 1950;132:839-41.
84. Urban JA, Baker HW. Radical mastectomy in continuity with en bloc resection of the internal mammary lymph-node chain. Cancer 1952;5:992-1008.
85. Veronesi U, Valagussa P. Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer 1981;47:170-5.
86. Lacour J, Le M, Caceres E, Koszarowski T, Veronesi U, Hill C. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 1983;51:1941-3.
87. Morimoto T, Monden Y, Takashima S, Itoh S, Kimura T, Yamamoto H et al. Five-year results of a randomized clinical trial comparing modified radical mastectomy and extended radical mastectomy for stage II breast cancer. Surg Today 1994;24:210-4.
88. Kaae S, Johansen H. Breast cancer; five year results: Two random series of simple mastectomy with post-perative irradiation versus extended radical mastectomy. Am J Roentgenol Radium Ther Nucl Med 1962;87:82-8.
89. Dupont EL, Kamath VJ, Ramnath EM, Shivers SC, Cox C, Berman C et al. The role of lymphoscintigraphy in the management of the patient with breast cancer. Ann Surg Oncol 2001;8:354-60.
90. Carcoforo P, Basaglia E, Soliani G, Bergossi L, Corcione S, Pozza E et al. Sentinel node biopsy in the evaluation of the internal mammary node chain in patients with breast cancer. Tumori. 2002;88:S5-7.
91. Dupont E, Cox CE, Nguyen K, Salud CJ, Peltz ES, Whitehead GF et al. Utility of internal mammary lymph node removal when noted by intraoperative gamma probe detection. Ann Surg Oncol 2001;8:833-6
92. Galimberti V, Veronesi P, Arnone P, De Cicco C, Renne G, Intra M et al. Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann Surg Oncol 2002;9:924-8.
93. Tanis PJ, Nieweg OE, Valdes Olmos RA, Peterse JL, Rutgers EJ, Hoefnagel CA et al. Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients. Br J Cancer 2002;87:705-10.
94. Morrow M, Foster RS Jr. Staging of breast cancer: a new rationale for internal mammary node biopsy. Arch Surg 1981;116:748-51.